Outlook Therapeutics (OTLK) Reports Positive Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Outlook Therapeutics, Inc. (OTLK) Phase 3 Data Supports Approval - Analyst
August 3, 2021 11:54 AM EDTEarlier today, Outlook Therapeutics, Inc. (NASDAQ: OTLK) announced positive clinical and highly statistically significant top-line results from its pivotal Phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010 / LYTENAVA (bevacizumab) - the companys lead drug candidate for treatment of neovascular... More
Outlook Therapeutics Incs. (OTLK) PT Raised to $6 at H.C. Wainwright
August 3, 2021 10:56 AM EDTH.C. Wainwright analyst Douglas Tsao raised the price target on Outlook Therapeutics Incs. (NASDAQ: OTLK) to $6.00 (from $5.00) while maintaining a Buy rating.
... MoreOutlook Therapeutics (OTLK) Climbs 41%
August 3, 2021 7:43 AM EDTOutlook Therapeutics (NASDAQ: OTLK) Climbs 41%
Earlier Outlook Therapeutics (OTLK) Reports Positive Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010... More